S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY

• Fritz Offner,
• Olivier Decaux,
• Cyrille Hulin,
• Sébastien Anguille,
• Anne Sophie Michallet,
• Luciano Costa,
• Cyrille Touzeau,
• Kevin Boyd,
• Deeksha Vishwamitra,
• Yue Guo,
• Zhuolu Niu,
• Julie Larsen,
• Lingling Chen,
• Arnob Banerjee,
• Jenna Goldberg,
• Jeffrey Matous

Affiliations

Fritz Offner

1 University Hospital Ghent, Ghent, Belgium

Olivier Decaux

2 Centre Hospitalier Universitaire de Rennes, Rennes, France

Cyrille Hulin

3 Hôpital Haut Leveque, University Hospital, Pessac, France

Sébastien Anguille

4 Vaccine and Infectious Disease Institute, University of Antwerp and the Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium

Anne Sophie Michallet

5 Centre Hospitalier Lyon Sud, Hospices Civils, Pierre Bénite, France

Luciano Costa

6 University of Alabama at Birmingham, Birmingham, United States

Cyrille Touzeau

7 Centre Hospitalier Universitaire de Nantes, Nantes, France

Kevin Boyd

8 The Royal Marsden Hospital, London, United Kingdom

Deeksha Vishwamitra

9 Janssen Research & Development, Spring House, United States

Yue Guo

9 Janssen Research & Development, Spring House, United States

Zhuolu Niu

10 Janssen Research & Development, Shanghai, China

Julie Larsen

11 Janssen Research & Development, Los Angeles, United States

Lingling Chen

9 Janssen Research & Development, Spring House, United States

Arnob Banerjee

9 Janssen Research & Development, Spring House, United States

Jenna Goldberg

12 Janssen Research & Development, Raritan, United States

Jeffrey Matous

13 Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, United States